Saudi Arabia Osteoporosis Drugs Market is expected to grow with the CAGR of 2.9% in the forecast period of 2022 to 2029. The years considered for study are as mentioned below.
The market osteoporosis drugs have witnessed increased strategic developments owing to favourable market scenario.
The major players dealing in Saudi Arabia osteoporosis drugs market are introducing strong range of products and adopting strategic initiative such as acquisition, agreement into the market. This helped companies to maximize the sales with enhanced product portfolio.
Amgen Inc. is the dominating player in Saudi Arabia osteoporosis drugs market. The other key players existing in the market includes Eli Lilly and Company, Novartis AG, Tabuk pharmaceuticals, SPIMACO, Hikma Pharmaceuticals PLC, Pfizer Inc., Merck KGaA, Apotex Inc., ABIOGEN PHARMA S.p.A., Sudair Pharma, tadawipharma., Fresenius SE & Co. KGaA, Hayat Pharmaceutical Industries Co. PLC and SAJA Pharmaceuticals among others.
Amgen Inc. is headquartered in California, United States. The company was established in 1980. The company is focused in transforming science and biotechnology into therapies that have the power to restore health or save lives. The company is dealing in only one business segment that is human therapeutics. The company has product categories including Prolia/XGEVA, Otezla, Aranesp, KYPROLIS, Repatha, Vectibix, Parsabiv, BLINCYTO, Aimovig, EVENITY, IMLYGIC in which the market focused categories are Prolia/XGEVA, and EVENITY.
The company is engaged in continuous development of osteoporosis drugs.
The company has wide presence across Asia-Pacific, Europe, North America, South America and Middle East & Africa. The company has various subsidiaries like Five Prime Therapeutics Inc. (U.S.), Immunex (U.S.), Amgen Switzerland AG (Switzerland), Amgen Australia Pty Limited (Australia) among others.
Eli Lilly and Company
Eli Lilly and Company is headquartered in Indiana, United States and was founded in 1876. The company is focused in manufacturing pharmaceutical product and to create medicines that make life better for people around the world. The company is dealing in one business segment, that is, human pharmaceutical products. the company has product categories including diabetes products, oncology products, immunology products, neuroscience products, and other therapies in which the market focused category is other therapies.
The company has wide presence across North America, South America, Europe, Middle East and Africa, Asia-Pacific. The company also has various subsidiary companies such AME Torreview LLC (Delaware), Andean Technical Operations Center (Peru), Applied Molecular Evolution, Inc. (Delaware), Avid Radiopharmaceuticals, Inc. (Pennsylvania) among others.
Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC has its headquarters in Amman, Jordan and was founded in 1978. The company is focused in developing, manufacturing and marketing a broad range of branded and non-branded generic medicines. The company has business segment such as Injectables, Generics in which the market focused segment is Generics.This company has product categories including US products, MENA products, Europe products, generic, and branded in which the market focused categories are MENA products and generic.
The company is engaged in continuous development of osteoporosis drugs and related products.
The company has wide presence across North America, Europe, Middle East and Africa.
Saudi Arabia Osteoporosis Drugs Market – Industry Trends and Forecast to 2029